head follow strong confid
guidanc estim
messag earn preview focu stock biotech
coverag report product sale despit neg market sentiment
fundament postiv bias follow strong confid guidanc
estim overal think gmab dc gwph
well posit rel expect expect bgne
celg zeal-dk perform line
increment posit bias head earn follow strong result
confid guidanc estim stock btk
vs continu downward trend btk vs
flat ytd vs despit strong earn result
predominantli driven growth product sale compani coverag beat
top-lin estim stock pull back howev macro backdrop
continu put pressur stock see figur time think
bar compani rais guidanc earn cycl may bit higher
view follow increas street consensu figur
coverag think gmab dc gwph
well-posit rel expect beat street estim potenti drive renew
confid group broadli overal think gmab dc well
posit rel investor expect head earn expect
bgne celg zeal-dk perform in-
line street expect appear high
ijem coverag gene therapi rare diseas commerci perspect
expect rel unev focu pipelin execut
upcom event particularli said alni onpattro
launch updat import though continu expect steadi progress limit
impact tafamidi see recent thought expect
rel flat vs consensu base prior trend fx headwind
expect in-lin quarter commentari around valrox acceler
approv file upcom vosoritid data readout like greater invest focu
im prescript trend suggest in-lin quarter continu growth volum
basi taf regimen stabil hepat milder generic letairi
think investor focu remain compani long-term strategi potenti
strategi provid increment updat competitor healthcar confer
januari expect investor focus reimburs progress
eu advanc earlier stage pipelin
darout coverag cardiovascular diseas like head number
meaning potenti catalyst could valid compani heart failur therapi
platform includ updat two mid-stag mavacamten non-obstruct hcm
well updat myok pioneer hcm studi mavacamten
obstruct hcm aha novemb zeal-dk dont expect mani
meaning updat year-end expect partner boehring
ingelheim privat could decid whether advanc once-weekli amylin program
diabetes/obes could novel intrigu approach chronic metabol
page analyst certif import disclosur
suneja coverag neurolog inflamm shape decent
across commercial-stag compani coverag univers expect see good
perform good perform complement franchis
ms franchis remain resili spinraza growth moder though still tick
biosimilar continu well overal expect consensu financi
perform gwph better expect epidiolex growth ds lg
see ingrezza beat steadi rate patient add larg continu
robust dupix growth resili perform eylea believ
compani like come ahead consensu believ name gwph
pois sharp rebound current low meanwhil visibl sage
zulresso sale limit though consensu appear reason overal expect
gwph come ahead consensu expect
come around street
schmidt coverag oncolog focu continu commerci execut
follow strong sale across board coverag expect investor
focu earn cycl remain continu sale trajectori momentum
drive sequenti quarter-over-quart growth particularli cabometyx darzalex
gmab jakafi adcetri investor continu focu
cabometyx rcc growth potenti launch trajectori ahead
result cabometyx street consensu look high
vs vs iqvia data decreas although could off-set partial
price increas inventori movement gmab could potenti benefit
recent maia approv posit data well season pick-up
sale follow typic slow summer month model darzalex sale
street consensu jakafi consensu estim
appear achiev view forecast less sequenti growth
strong sale view could potenti result rais guidanc near
term investor await updat gvhd phase trial guid sale
expect adcetri look reason qoq growth view given strong
sale histor growth pattern expect investor focu near-term pipelin
regulatori updat three late stage product candid enfortumab vedotin tucatinib
tisotumab vedotin given upcom news flow tucatinib deep dive
gmab initi think recent may approv line aml could support
tibsovo growth expect look reason bgne sale
rel unaffect recent nationwid expans china central procur
list celg remain track meet guidanc investor focu recent
shift back cvr-relat asset ozanimod liso-cel
key event next month despit low street expect expect
remain range-bound given continu fundament concern growth outlook
rubraca nerlynx respect nerlynx sale could potenti benefit recent
price increas earli septemb sinc launch expect
investor focu underli volum trend price action current rate may
sustain
page analyst certif import disclosur
page analyst certif import disclosur
figur quarter quarter chang consensu estim total revenu
page analyst certif import disclosur
buy focu remain tibsovo launch trajectori investor await pipelin updat
takeaway tibsovo sale recov last quarter follow disappoint management primarili attribut season factor investor like focu
near-term growth driver tibsovo follow recent posit datapoint broader-than-expect aml approv may ii posit claridhi data
recent present esmo valu stock pipelin current view posit news drive potenti upsid potenti financ need
form overhang stock
factset consensu guggenheim secur llc
forecast revenu includ tibsovo sale vs street consensu respect
recent may snda approv tibsovo slightli broader-than-expect frontlin aml patient popul could addit increment growth
driver expect investor interest effect tibsovo demand first three potenti newli diagnos aml market segment also
context recent venclexta launch
management confirm remain track file snda tibsovo cholangiocarcinoma base recent present claridhi dataset esmo link
initi dose escal data monotherapi arm present tripl meet per management guidanc data
present could clear event stock view investor sentiment around platform declin follow increas skeptic
singl agent activ potenti given preclin data pursu develop plan instead evalu combin taxan
enrol pivot ph trial evalu mitapivat pyruv kinas defici pkd activ activate-t track complet
year end top-line data like avail view
rais tibsovo estim slightli reflect momentum frontlin aml util
recent upgrad link given under-perform year vs btk investor sentiment pipelin declin
absenc news flow key compon prior neutral thesi howev current valuat reflect valu beyond tibsovo/idhifa view
even updat conserv estim believ tibsovo alon worth idhifa royalti celg believ
provid floor valuat mitapivat high po pivot trial doc feedback highlight moder real commerci
opp ty pkd still think low po program ph data could potenti clear event
page analyst certif import disclosur
buy enrol attr-cm patient apollo-b trial focu
top-line data lumasiran studi later year
takeaway estim revenu line consensu primarili driven increas sale onpattro
on-going global launch expect investor focu remain onpattro launch attr market dynam enrol alni attr-cm trial
continu think near term onpattro number achiev longer term competit headwind price pipelin
expect givosiran also topic discuss ahead potenti launch patient number launch prep price earli lumasiran
given recent competit updat thought upcom pivot data readout
factset consensu guggenheim secur llc
forecast sale larg line consensu repres growth recal last quarter
patient world-wide commerci onpattro vs patient management guid continu steadi growth quarter quarter ad
june regulatori approv onpattro japan expect signific market drug futur
forecast opex expenditur line consensu recal compani guid non-gaap expens
non-gaap sg expens year cash share outstand end
dilut ep estim vs street dilut ep
wed note beat ep last quarter miss
expect major investor discuss focu onpattro domest sale well ou launch helios-a/b trial subcutan
vutrisiran remind septemb initi apollo-b ph studi patisiran attr-cm amyloidosi patient wt/ani attr
mutat thought trial vutrisiran helios-b trial design
also expect see investor focu top-line data lumasiran ph trial illuminate-a expect report later year
launch givosiran earli next year us/eu follow potenti regulatori approv
clinic program trial readout later year could also focu call includ aatd initi data ph studi
initi ph data aln-agt studi hypertens
longer term outlook remain buy-rat think near term onpattro number achiev competit risk tafamidi price
level see doc survey thought encourag compani expand pipelin preclin engin
page analyst certif import disclosur
earn follow good expect revenu come estim street though note
consensu revenu estim may somewhat incomplet non-gaap ep also like beat consensu estim given opex leverag
complement franchis perform well sale like consensu forecast complement franchis sale come least in-
line street consensu driven continu robust uptak neurolog franchis includ gmg assum q/q patient growth vs
growth previou two quarter revenu recent approv nmosd rel flat q/q growth core pnh
ahu indic benefit one extra infus day quarter worth off-set modest headwind
price reduct canada favor order time recal pnh patient convert soliri ultomiri
month launch month assum pnh convers rate continu progress per month sight
reduct rate would expect pnh patient convert soliri end addit ultomiri market
three quarter mani patient alreadi move larger mainten dose level also result slightli higher sale estim
patient convert ultomiri end sale thu compani hit estim convers end
would expect see ultomiri sale rang line consensu slightli note
suffer net neg impact favor order time ahead juli holiday neg canada follow
judici order price reduct canada like provid headwind could see soliri revenu come ahead
consensu overal believ total complement franchis sale could come ahead
consensu
metabol portfolio perform line forecast metabol portfolio come line street consensu q/q y/i
new price strategi surround weight-bas dose regimen go provid headwind throughout
fx provid littl impact top-line usd remain within fairli narrow band within euro see oecd data
hover around dollar depreci rel jpi assum eu sale japanes
sale see total currenc impact eu sale less hedg impact japanes sale effect net near zero
addit note ex-u revenu hedg reduc fx impact
page analyst certif import disclosur
ultomiri ultomiri regulatori file ahu accept prioriti review could like result approv around octob pdufa
date would expect ultomiri adopt rate ahu similar pnh phase trial nmosd slate begin toward
fcrn antibodi continu progress phase i/ii trial initi phase ii/iii trial waiha mg pv
longer term outlook remain neutral-r base view current valuat adequ captur lack near-term growth
pipelin rel defens commerci posit embodi ultomiri launch moreov compani current face ip headwind eu
 see note alxn ip situat
page analyst certif import disclosur
bgne buy earlier-than-expect us regulatori submiss china approv commerci roll-
track
takeaway current sale three legaci product china abraxan revlimid vidaza bgne aquir celg part collabor
despit competit local gener drug believ singl digit low teen qoq growth three product achiev
zanubrutinib nda submit earlier expect us pdufa date feb anticip tislelizumab china approv approach management guid
expect investor continu predominantli focu regulatori decis well key pipelin updat includ zanubrutinib pivot trial result later
year
factset consensu guggenheim secur llc
revenu forecast roughli line consensu sequenti revenu decreas result elimini collabor
incom due termin tislelizumab collabor celg
deriv sale forecast assum qoq growth abraxan competiton hengrui gener product revlimid
nrdl modest competit beij sl pharma gener product vidaza nrdl
recent lunch bgne management note expect three product includ central procur list near
term therefor expect impact recent price-cut nationwid expans china central procur
china nda tislelizumab chl remain regulatori review decis guid
us nda zanubrutinib mantl cell lymphoma mcl submit pdufa target action date feb
top-lin result random cohort vs imbruvica zanubrutinib phase aspen trial guid
top-lin result us pivot phase ii trial tislelizumab liver cancer guid
near-term sale slightli lower account moder abraxan growth
remain buy-rat bgne potenti upsid view tie rich set pipelin regulatori mileston two intern develop
program zanubrutinib tislelizumab compani continu expand portfolio oncolog drug
page analyst certif import disclosur
neutral expect top/bottom-lin investor focu remain potenti activ
takeaway ms franchis remain resili spinraza growth moder though still tick biosimilar continu well
earn expect report revenu consensu q/q y/i estimate
good perform three franchis ms sma biosimilar bottom line believ consensu non-gaap ep readili achiev
ms portfolio follow good script q/q im script data suggest slight drop q/q overal ms market note
biib ms franchis impact inventori drawdown thu assum similar level re-stock despit weak
overal market expect biib ms franchis sale come around street
spinraza recal sale new patient add slight increas averag dose/pati vs
despit nvss zolgensma launch expect similar number new patient add enough bring sale closer
q/q eu sale vs benefit price adjust franc well ship time given
page analyst certif import disclosur
inventori impact estimate salesest ex-u salesest global sale vs initi gs estimate street estimate vs drawdown drawdown ms global royalti exclud fampyra estim gener salesoveral sec file factset guggenheim secur llc analysi rx data base iqvia estimatesoveral ms franchis drug q/q ww sale predict vs gs model street drawdown
manag commentari mid-singl digit growth matur eu market coupl signific growth turkey doubl digit growth apac european
sale like come q/q overal expect global sale q/q consensu q/q
biosimilar limit visibl expect line result benepali/flixabi believ imraldi success launch continu sale come
closer q/q vs street q/q overal estim biosimilar sale q/q vs street q/q
longer term outlook remain neutral-r recent setback alzheim competit sma dynam intrigu distant pipelin
page analyst certif import disclosur
neutral vosoritid data look pipelin refresh day
takeaway estim revenu in-lin consensu said think focu call like
statu valrox acceler approv file upcom vosoritid data readout moreso latter given data
readout data day novemb beyond valrox vosoritid believ limit meaning clinic catalyst
next month though look forward new updat bmrn day
factset consensu guggenheim secur llc
forecast sale roughli in-lin consensu kuvan vs street palynziq vs street in-lin
consensu dilut ep estim compar street dilut ep
believ investor focu remain palynziq launch pipelin program in-lin consensu remain cautiou market
opportun daili subq product assum patient grow penetr fulli reimburs patient compar reimburs
patient
slightli consensu aldurazym vs street note manag previous comment recogn
beat ep last quarter beat
expect major investor discuss focu progress toward valrox file updat progress packag
acceler approv clinic side think persist question varianc phase phase result expect
detail day rather call base previou comment
expect increas focu vosoritid given compani expect data late said continu think potenti upsid near
term program rel limit wed note emerg competit landscap
host day novemb compani plan discuss valrox steroid consider vosoritid data bmn
pku detail new pipelin program
page analyst certif import disclosur
slightli adjust interest incom dilut ep increas prev maintain neutral
remain neutral-r base continu think near-term option price struggl see could surpris upsid
continu believ competit updat hemophilia achondroplasia could repres headwind
page analyst certif import disclosur
celg data disclosur time liso-cel remain top mind investor
takeaway follow august announc otezla bought lofti link investor focu shift back cvr-
relat asset ozanimod liso-cel ozanimod review fda pdufa date march investor await updat
celg car-t franchis liso-cel top-line data report year end per manag guidanc
factset consensu guggenheim secur llc
forecast revenu opex dilut ep compar street consensu respect
current revenu guidanc repres growth achiev view given celg high exposur
beginning-of-year dynam deduct reset co-pay card util etc pose headwind earli month sale grew
nda ozanimod multipl sclerosi luspatercept beta thalassemia myelodysplast syndrom md respect accept
current fda review pdufa date respect
top-line result pivot trial liso-cel transcend-nhl karmma guid year end file guid
respect multipl myeloma/anti-bcma deep dive
septemb celg announc ph quazar studi oral vidaza newli diagnos aml patient met primari endpoint celg
track file regulatori submiss
januari celg also guid toward clinic data updat anti-bcma t-cell engag mab
given pend acquisit remain neutral-r celg current share price offer littl upsid potenti given acquisit offer
cash share conting valu right cvr
page analyst certif import disclosur
neutral expect continu commerci headwind rubraca driven competiton
takeaway expect share remain rangebound given continu investor concen around compani high leverag level convert
debt plu royalti financ continu commerci headwind key market rubraca recurr ovarian cancer maintain market continu
grow slowli remain competit market demand suppli free drug new competit front-lin ovarian cancer maintain
azn gsk pose addit commerci headwind come year view prima trial brca prostat cancer could potenti provid
increment growth opportun rubraca think categori may becom even competit ovarian parp inhibitor like
market
factset consensu guggenheim secur llc
rubraca sale forecast vs in-lin street consensu
investor still question commerci opportunity/growth potenti parp inhibitor recurr ovarian cancer mainten therapi competitor move
ovarian cancer treatment repres addit headwind pivot athena trial read per management guidanc
rubraca sale flat vs despit commerci launch germani uk march
reiter guidanc esmo congress snda submiss rubraca mcrpc
develop program aim expand rubraca label wont complet
recent acquir right fap-target radiopharmaceut preclin program pharmaceut ind submiss guid
updat reflect recent convert debt financ close aug
expect share remain rangebound given continu investor concen around compani high leverag level debt continu
commerci headwind key market rubraca catalyst line-up limit key rubraca trial read
page analyst certif import disclosur
buy growth exist market new indic busi develop question
takeaway investor continu uncertain sustain cabometyx growth given on-going competit dynam rcc potenti growth trajectori
new concern recent anda file think consensu high given street assum net sale growth despit iqvia data
point cabometyx trx declin vs could partial off-set list price increas juli much reflect valuat
view believ potenti cabometyx indic expans well pipelin growth potenti sourc upsid longer term
investor continu uncertain sustain cabometyx growth given on-going competit dynam rcc potenti growth trajectori
estim product sale vs consensu consist sale qoq broken
rcc qoq qoq cometriq sale qoq estim base iqvia actual
estim captur rate adjust result qoq demand
account list price increas begin adjust gross-net last quarter
channel in-stock could potenti help sale given exist inventori low end histor level
stock remain single-product stori albeit consider growth potenti via indic expans opportun
on-going ph trial rcc opdivo result opdivo yervoy initi
on-going ph trial combin tecentriq random vs nexavar bayri initi
ph differenti thyroid carcinoma initi repres potenti sourc upsid estim
model updat modestli reduc near-term sale forecast account recent iqvia script data pt remain
remain buy-rat base view cabometyx continu grow longer term rcc given statu prefer tki
potenti use combin pend posit data near-term growth oppti long-term expans oppti
label extens indic
page analyst certif import disclosur
buy gene therapi galafold growth continu captur investor interest
takeaway estim revenu line consensu repres growth revenu
compani guid fabri patient galafold continu believ achiev expect discuss
continu focu us dynam newli launch geographi look pipelin expect discuss also focu larg
upcom updat cohort ert-switch patient data oct world muscl meet addit data
interim clinic result studi analyst day oct annual meet oct also listen
enrol updat compani on-going trial at-gaa pomp trial
factset consensu guggenheim secur llc
forecast galafold sale vs con repres growth
compani continu guid patient patient global apr previous note
highest quarter growth sinc galafold launch captur global market share treat amen fabri patient growth come
switch nave patient
manag also previous comment consist galafold adopt trend order pattern previou year quarter-over-quart
revenu growth trend like non-linear higher growth year recal management previous iter
revenu yoy constant currenc revenu growth off-set neg currenc impact expect fx
headwind ex-u sale rest year guid revenu rang estim revenu galafold year
model opex expenditur line consensu estimate
dilut ep estim vs street dilut ep
wed note beat last quarter miss
expect signific amount focu upcom addit data readout fold lead gene therapi program meet
also listen updat progress earlier stage cln program in/mov toward clinic
pipelin mover includ updat preclin poc fabri pomp diseas gene therapi expect public meet
throughout year intend select pomp aav gene therapi clinic candid move ind-en studi year
page analyst certif import disclosur
compani also present addit data at-gaa studi
also continu look forward updat fold/upenn collab new gene therapi lsd rare diseas
longer term outlook remain buy-rat expect galafold launch continu perform well at-gaa expect appropri set
point thing combin compani emerg gene therapi focu lead upsid remaind year
page analyst certif import disclosur
buy busi stabil await game
takeaway forecast revenu vs consensu focu remain compani long-term strategi ceo
daniel oday plan discuss increment updat competitor healthcar confer januari think investor focu continu
potenti given still strong cash posit potenti updat team compani still search new cfo
cso expect in-lin quarter driven prescript trend show continu growth volum basi taf regimen stabil
hepat milder generic letairi estim addit look color surround potenti filgotinib descovi
prep launch continu think gilead remain attract valu base busi stabil appear justifi valuat even
exclud pipelin opportun risk/reward skew upsid
factset consensu guggenheim secur llc
estim revenu in-lin consensu continu think taf grow driven growth biktarvi vs
consensu descovi vs consensu though note result declin genvoya vs consensu im health
prescript data suggest slower truvada volum growth yoy vs forecast higher biktarvi growth yoy
hcv hbv prescript trend week end sep suggest stabil particularli volum gener epclusa hcv
product volum sequentially/yoy volum basi hbv product stabil sequentially/yoy
recent generic letairi prescript trend indic sharp declin sequenti volum basi though appear less
aggress forecast vs consensu
opex consensu though note factset consensu seem add glpg transact cost
vs expect hear commerci plan filgotinib descovi prep
wed note beat non-gaap ep last quarter beat
page analyst certif import disclosur
think filgotinib prep commerci focu call plan submit filgotinib prep fda file
descovi prep pdufa expect
expect data sjogren syndrom cutan lupu erythematosu filgotinib lupu sjogren syndrom
nash continu wait-and-se atla combin studi top-lin data expect recent competitor confer mr oday
hiv compani also expect phase data earlier stage candid
reiter previou comment atla result would determin level go-forward strategi invest toward nash
hematology/oncolog provid updat academ confer throughout compani also plan initi allogen kte-
hbv expect data phase studi
updat near-term estim ahead result pt remain
remain buy-rat base continu view base busi posit well taf launch prep tailwind
predict hcv new ceo daniel day strategi thu far appear larg unchang anticip discuss long-term strategi
vision later year increment updat jan think bar rel low sentiment shift/upsid
page analyst certif import disclosur
gmab dc buy dkk darzalex frontlin penetr like gain steam focu shift pipelin
takeaway gmab proprietari pipelin progress clinic investor focu remain darzalex royalti stream full quarter post-
maia approv darzalex part drd multipl myeloma see mm deep dive investor focus darzalex util frontlin mm
largest mm commerci opportun evolv recal management guid toward potenti achiev doubl digit share mm year-end expect investor focu
shift away darzalex come quarter toward proprietari pipelin clinic data get present asset achiev clinic poc
factset consensu guggenheim secur llc
estim dkk revenu street consensu dkk dkk opex street consensu dkk
investor focu remain darzalex royalti stream particularli given first full quarter post-maia approv key frontlin mm label
extens darzalex franchis ii includ posit dataset studi evalu drvd quad regimen could lead
off-label use set forecast dkk darzalex royalti gmab base sale street consensu dkk
impli sale
gmab guidanc includ dkk revenu includ dkk darzalex royalti assum exchang rate
gmab partner submit darzalex sc file decis expect per guidanc addit gmab partner novn swx
track file ofatumumab snda treatment relaps multipl sclerosi base asclepio data recent present ectrim link
full dataset potenti pivot innovatv studi evalu lead proprietari product tisotumab vedotin r/r cervic
cancer expect read per management guidanc
initi data ph dose escal trial evalu duobodi cell malign expect per management guidanc
initi data ph dose escal trial evalu hexabodi solid tumor expect year end per management guidanc
believ gmab differenti antibodi technolog platform multifacet repres strong product engin support long-term growth
compani view gmab current valuat predominantli base darzalex royalti partner cash balanc sheet
littl valu attribut proprietari out-licens pipelin product candid sever potenti catalyst line next month
posit could potenti result addit valid gmab pipelin support upsid street consensu estim
page analyst certif import disclosur
gwph buy epidiolex anoth solid quarter snda track
takeaway gwph expect sale beat base management /kol feedback rx analysi
gwph report solid epidiolex sale beat vs street expect anoth solid quarterli perform drug
analysi data see iqvia suggest continu m/m growth script recent manag commentari see suggest
iqvia rx data accur measur short term trend interpret cautious compani continu see steadi rate
new patient start nonetheless even use conserv assumpt base growth trend arriv sale estim
support compani commentari indic patient take epidiolex end even q/q
growth patient add vs management kol feedback steadi number new patient start would annual annual sale
view epidiolex sale level consensu well-receiv investor epidiolex util
weight-bas dose compani note mani patient still low end titrat curv coupl increas older
heavier patient get drug may translat even higher sale figur launch continu
follow posit pivot data tuber sclerosi snda target compani expect present addit data
decemb note common seizur type patient focal seizur suggest data could dramat expand
epidiolex label address epilepsi popul
remain buy-rat gwph base posit view continu epidiolex launch european market well expect
approv epidiolex next year gener new bolu patient come drug
page analyst certif import disclosur
gwph plc diff gscon diff gscon diff gscon diff epidiolex oper sec file factset price guggenheim secur llc analysi consensu estim compil biotechnolog
buy quarter jakafi competit mf focu continu momentum pipelin updat
takeaway follow strong patient demand lead product jakafi first half year rais lower end fy jakafi guidanc
show increas convict despit recent approv jakafi first competitor myelofibrosi mf celg fedratinib street larg view
fedratinib inferior given high rate observ gi toxic well-establish posit jakafi provid first glimps evolv
market dynam addit expect investor focu pipelin updat street continu look progress toward ad addit
commerci product portfolio
factset consensu guggenheim secur llc
forecast revenu slightli consensu higher opex vs thu lower dilut ep vs
product level consensu model jakafi sale vs iclusig sale vs rais jakafi list
price could potenti affect inventori dynam toward end
note expect major jakafi growth come volum oppos anticip price action includ
current approv indic mf pv well contribut recent approv agvhd
meet current jakafi guidanc requir growth could achiev view given grown
vs strong sale view could potenti result rais guidanc
pivot data cholangiocarcinoma recent present esmo link nda file track year end
data updat graft-versus-host diseas gvhd program includ ph result jakafi steroid-refractori acut gvhd ph
result jakafi steroid-refractori chronic gvhd ph result itacitinib steoid-nav agvhd track
pivot true-ad program evalu topic ruxolitnib atop dermat remain on-going data expect next year per management guidanc
follow regulatori meet initi pivot ph vitiligo program topic ruxolitinib follow posit ph ii top-line data link earlier year
remain buy-rat base convict sustain jakafi growth approv indic addit upsid potenti ruxolitinib
topic dermatolog opportun includ atop dermat vitiligo frontlin gvhd opportun itacitinib well pemigatinib potenti
fgfr-posit bladder cancer addit pipelin candid repres potenti upsid estim
page analyst certif import disclosur
buy catalyst-rich provid valid mava clariti opportun
takeaway like head number meaning catalyst valid compani heart failur therapi platform
critic event remain pivot phase data mavacamten obstruct hypertroph cardiomyopathi hcm genet heart failur disord
well get updat two mid-stag mavacamten non-obstruct hcm repres heart failur patient base
estim futhermor expect get updat myok pioneer hcm studi mavacamten obstruct hcm aha
sec file factset consensu guggenheim secur llc
model revenu potenti launch mavacamten obstruct hcm
management reflect expens reduct cash invest part myok agreemet acquir sanofi san-fp buy
royalti us sale mavacamten
phase maverick top-line mavacamten patient non-obstruct hcm
phase top-line patient dilat cardiomyopathi
phase explor top-line mavacamten patient obstruct hcm
lead asset mavacamten potenti first-in-class therapi obstruct hypertroph cardiomyopathi hcm option non-
obstruct hcm current phase maverick trial read believ upcom updat pioneer-hcm data
mavacamten obstruct hcm phase maverick-hcm data provid valid mavacamten potenti hcm serv
posit read-through pivot data platform recogn risk inher unchart mechan therapi cardiovascular
diseas view underappreci biotechnolog compani cardiovascular diseas
page analyst certif import disclosur
neutral expect anoth quarter ingrezza orilissa continu lag
takeaway expect nice beat ingrezza possibl updat fda discuss trial adult
ingrezza ingrezza sale q/q y/i well ahead consensu estim
histor third parti data less reliabl recent script growth trend entir correl compani report number
note iqvia q/q show slightli slow q/q growth email us ingrezza rx tracker line compani commentari
gener weaker quarter q/q growth would impli revenu exclud q/q inventori build-up
get net sale number vs consensu acknowledg iqvia data might less reliabl though pretti
accur altern method also look absolut number script add q/q one assum net increment prescript
volum growth averag prior quarter note averag last two quarter get increment q/q revenu
increas impli sale incorpor inventori build-up net sale like
come closer net-net expect ingrezza sale come consensu
orilissa recal receiv royalti net sale orilissa current approv endometriosi
orilissa sale came vs impli consensu sale translat royalti
royalti rate manag attribut miss payor dynam frequenc doctor visit popul lower
guidanc maintain long-term outlook sale model royalti payment
impli total sale q/q base continu slow trajectori per script data launch far believ orilissa
sale like come slightli consensu estim avail trx data iqvia indic q/q growth entir
captur would translat royalti base royalti
juli compani initi adapt phase ii poc studi evalu safeti pk/pd pediatr patient classic data
expect meanwhil expect get clariti compani plan trial adult patient fda discuss
voyag januari enter partnership develop gene therapi program compani
expect present extend durabl data one asset vy-aadc parkinson later year expect updat call
remain neutral-r base limit increment growth opportun ingrezza lack meaning near-term catalyst
page analyst certif import disclosur
neutral continu growth momentum nerlynx slowdown
takeaway despit small sale beat last quarter remain skeptic nerlynx longer term commerci growth potenti given drug safety/efficaci
profil potenti unfavor market dynam earli breast cancer well significat competit relapse/refractori set street model
nerlynx sale growth could driven recent implement program design increas patient util decreas discontinut
due advers event
factset consensu guggenheim secur llc
forecast revenu includ nerlynx sale vs street consensu respect took second
price increas yield combin price increas sinc launch
earlier year saw high number patient termin therapi upon complet year nerlynx treatment approv label
increas discontinu rate decreas util follow dose delay modif increas gross-to-net adjust higher-
than-averag vacanc rate sale forc result sale territori sale rep point
nerlynx came slightli expect still management attribut lower gross-to-net adjust vs
ii new hire brought fill prior sale repres role vacanc iii increas educ around side effect manag
given guidanc nerlynx sale sale would need demonstr growth recal sale grew
sale expect rais guidanc
fda recent accept nerlynx snda treatment mbc base ph nala trial link pdufa date set late april
addit data summit trial expect per management guidanc addit guid meet fda discuss
clinic develop regulatori strategi summit trial
updat estim reflect price action
remain neutral-r base cautiou view regard nerlynx longer term commerci growth potenti given drug safety/efficaci
profil potenti unfavor market dynam earli breast cancer well significat competit relapse/refractori set
page analyst certif import disclosur
buy expect across board dupix deliv anoth strong quarter
takeaway dupi continu deliv eylea like maintain resili could still mileag left libtayo inflect like
possibl interim nsclc data readout praluent kevzara keep tri like remain disappoint
earn expect eylea sale least meet consensu upsid driven new diabet retinopathi indic uptak recent avail pre-fil
syring formul dupix continu perform like champ reach all-tim high like fuel robust uptak recent approv
indic asthma adolesc atop dermat continu uptak dermat even account expand channel benefit sale q/q
sale growth look pois increas indic total sale could come well ahead street
meanwhil iqvia data suggest uptick praluent weekli q/q could lead narrow beat street
estim kevzara trx q/q would put sale roughli street final limit visibl
libtayo given first-in-class label cutan squamou cell carcinoma patient limit treatment option demand robust expect
slight beat consensu
long term outlook recent upgrad rate buy base view competit headwind eylea franchis
manag concern distort price eylea fairli reflect current valuat result ad clariti lead signific
appreci share price street substanti under-appreci market opportun dupix peak sale potenti
expect drive signific leverag sni antibodi collabor recent becam profit
page analyst certif import disclosur
sale base recent script trend q/q initi gs estimate street estimate vs gsv streetg commentseylea limit visibl though consensu appear achiev expect modest benefit new diabet retinopathi indic pre-fil syring kol check indic dupix game changer across multipl atop diseas expect anoth solid quarter incorpor q/q inventori consensu data show nice uptick though impact cvot label chang yet limit visibl consensu achiev signific potenti grow csccsourc sec file factset guggenheim secur llc analysi rx data im estim
buy zulresso pois slow launch though consensu achiev eye
mountain data
takeaway expect slow zulresso launch site get registr process come on-line mdd data key n-t catalyst
launch first commerci product zulresso iv gaba-a posit alloster modul approv post-partum depress june
drug gener sale made entir channel stock base kol feedback continu expect slow launch given
dose schedul continu infus novelti rapid-act treatment reimburs challeng relat high price
price assum discount patient would need undergon treatment reach consensu estim
respect believ number readili achiev compani despit strict site approv requir
report call healthcar facil cover potenti popul rem certifi though full site activ take
month compani still need establish site protocol formulari access secur payor author manag believ
launch momentum build site come fulli on-line
data phase mountain studi mdd oral gaba-a receptor modul expect per manag
pivot event compani failur trial would thesis-chang event compound
compani expect initi phase ii trial oral gaba-a pam treat essenti tremor alreadi produc promis phase
top-line data nmda receptor pam phase trial patient huntington expect
remain buy rate continu posit view upcom mountain trial mdd continu expect
posit result po studi readout see potenti move stock safeti durabl trial
key determin futur uptak depress
page analyst certif import disclosur
buy focu shift pipelin sustain adcetri growth front indic
takeaway sale expect adcetri look reason view given strong sale histor pattern exect investor focu near-
term pipelin regulatori updat three late stage product candid enfortumab vedotin tucatinib tissotumab vedotin given recent esmo data link
upcom newsflow read preview genmab initi
factset consensu guggenheim secur llc
adcetri sale forecast vs in-lin street consensu
implement gross price increas end jun howev histor off-set increas gross-net adjust
re-affirmed adcetri sale guidanc achiev first two quarter flat sale throught rest
could meet lower-end fy guidanc qoq growth could beat upper-end
pdufa-d enfortumab vedotin patient relapsed/refractori urotheli cancer uc march esmo management guid initi
pivot trial line muc later year
tucatinib evalu pivot studi breast cancer patient top-lin result guid
pivot tissotumab vedoin phase ii result recurr cervic cancer w/ gmab guid
adcetri label expans activ includ two on-going phase trial evalu combin adcetri opdivo front-lin relaps chl
updat reflect recent equiti financ close jul
continu believ well posit outperform group driven continu adcetri growth approv indic well pipelin
news includ pivot trial result tucatinib breast cancer pivot trial result tisotumab vedotin trial
relapsed/refractori metastat cervic cancer accord gmab/sgen well posit trial result out-licens program gsk-ln
page analyst certif import disclosur
neutral expect investor focus reimburs progress eu
progress expand pipelin
takeaway estim revenu larg line consensu estim cf think focu continu
reimburs discussions/progress eu though assum get resolv model well upcom tripl launch
emerg pipelin think discuss larg focu compani earlier stage fsg program clinic
well preliminari data updat b-thal/scd studi crsp later year/earli next year also listen color
compani recent acquir diabet program thought progress gene therapy/edit space dmd thought
factset consensu guggenheim secur llc million except per-shar data
forecast cf sale line consensu vs street current forecast total cf sale year vs street
estim
compani guid combin non- sg expens combin sg expens
forecast total opex non-gaap vs street non-gaap tax rate guidanc remain
non-gaap dilut ep estim larg in-lin street non-gaap dilut ep
wed note beat last quarter beat beat
expect focu potenti initi data updat vrtx/crsp hemoglobinopathi program
progress vrtx inhibitor fsg current studi patient zz mutat current advanc
dose-rang studi would also begin draw investor interest
page analyst certif import disclosur
also view vrtx recent acquisit posit compani expand pipelin beyond cf await
addit news timelin given semma previous guid clinic readi
discuss around new effort dmd also interest follow vrtx acquisit exon therapeut extend collabor
crsp addit well listen commentari braider plans/strategi gene therapi overal follow recent hire dr john gray
model updat revis near-term estim ahead result maintain neutral rate
longer term outlook remain neutral-r think success tripl combo alreadi price await updat earlier stage
pipeline/addit valu driver pain/aatd/fsg program beta-thal/scd program crsp well recent ad
page analyst certif import disclosur
zeal-dk buy dkk despit littl catalyst ye continu recommend
takeaway expect earn non-ev zealand follow recent posit phase announc dasiglucagon pediatr patient
sever hypoglycemia sh dont expect mani meaning updat year-end expect partner boehring ingelheim
privat make decis once-weekli amylin program diabetes/obes could novel intrigu approach chronic metabol
sec file factset consensu guggenheim secur llc
dont forecast revenu zeal-dk anticip compani book relat initi partner glp-
dual-agonit program boehring ingelheim
earn call zealand management revis net oper expens full-year upward dkk dkk
mainli due acceler build-up us commerci infrastructur dasiglucagon hypop rescu pen sever hypoglycemia well
addit spend next-gen asset short bowel syndrom dasiglucagon congenit hyperinsulinsm program
forecast opex expenditur dkk vs consensu estimate dkk dkk
phase top-line glepaglutid agonist patient short bowel syndrom
phase top-line dasiglucagon children congenit hyperinsulin
phase result patient short bowel syndrom
remain buy-rat zealand given opportun see upsid stock near- medium-term zealand advanc
potenti best class program diabet short bowel syndrom repres meaning opportun pivot data three program
read zeal-dk also three out-licens product boehring ingelheim subject near-term royalti
mileston set number potenti updat next month
page analyst certif import disclosur
zeal-dk zealand pharma dkk diff gscon diff gscon diff gscon diff total oper na- na- na-
valuat risk
buy valuat valu use discount cash flow analysi though use wacc consist
commerci stage compani cover well termin growth rate risk regulatori commerci setback potenti emerg new
competitor lower product sale expect risk intellectu properti risk manag execut
buy valuat price target per share base dcf analysi includ current busi well probabl
weight pipelin revenu assum discount rate termin growth risk suscept risk appli entir biotech
industri includ develop regulatori commerci manufactur financ ip risk specif includ clinic risk concentr
effort pioneer rnai therapeut howev accept risk scientif evid support feasibl therapi still
limit face skeptic base so-cal off-target effect activ interferon respons drug candid demonstr efficaci laboratori
set may translat well human clinic trial notabl unexpect safeti issu may aris lead program could read-through
entir platform/pipelin regulatori risk even develop stage candid clinic trial ultim success possibl alni medicin
approv global regulatori agenc given novelti rnai technolog human use agenc may requir addit long-term data could
delay potenti approv commerci risk limit experi commerci compani onpattro first commerci product given natur
diseas possibl may challeng identifi patient gain market share rel competitor run commerci risk
encount uncertainti commercializing/distribut onpattro drug competitor risk develop therapi area treatment option
limit possibl risk/benefit alni therapi may favor effect intens competit pharmaceut market also
antisens oligonucleotide/gen therapy/gen edit compani develop potenti competit medicin possibl therapi could prove
better safeti efficaci captur larger market share
neutral valuat pt assum alexion trade mean similar compani ep estim support risk-
adjust npv forward price-to-earnings compar analysi yield pt valu share use forward price-to-earnings multipl analysi look
price-to-earnings multipl select biotech pharma compani similar invest profil alexion compani trade consensu earn
estim offer averag ep compound-annual-growth-rate project ep compound-annual-growth-rate think l-t sustain franchis
light competit remain concern therefor share unlik trade premium peer appli mean multipl non-gaap
ep arriv pt net-present-valu npv analysi support p/e-bas pt includ cash flow alxn base
busi approv product current net cash discount rate termin growth rate upsid price target
current level maintain neutral rate base lack near term catalyst could larg impact share price risk includ failur
secur approv soliri nmo slower expect growth mg upsid risk includ substanti larger expect growth soliri sale nmo
larg growth pnh/ahu popul treatment
neutral valuat pt assum trade ep estim support risk-adjust npv account
recent clinic setback alzheim robust competit horizon sma ip risk intrigu distinct pipelin believ trade
discount peer larg cap biopharm compani multipl thu assign price-to-earnings multipl forward price-to-earnings compar analysi yield pt
downsid risk includ addit failur alzheim asset tecfidera ipr decis upsid risk includ unexpect success
alzheim asset less competit sma unexpect commerci growth rest pipelin
bgne buy valuat valu bgne per share use dcf base valuat method valuat includ commerci product bgne
acquir celg part collabor includ abraxan revlimid vidaza well probability-adjust cash flow deriv drug
candid develop zanubrutinib tislelizumab pamiparib use discount rate consist commerci stage biotech
compani coverag termin growth rate appli termin year post patent expir compar similar compani
coverag risk risk valuat bgne includ regulatori commerci setback potenti emerg
new competitor /or lower product sale expect risk intellectu properti risk manag execut misstep
page analyst certif import disclosur
neutral valuat base dcf analysi believ fairli valu forecast probability-weight revenu expens
assum discount rate termin growth rate invest risk suscept risk appli entir biotech industri
includ develop regulatori commerci manufactur financ ip risk specif includ commerci risk downsid risk
medicin target diseas small patient popul possibl compani may fail introduc new product market current product could
produc less revenu expect patient identif may slower expect product may receiv unfavor payor reimburs upsid risk
possibl market share assumpt conserv preval bmrn target diseas could prove larger current model
clinic risk downsid risk sever key pipelin product still clinic develop may delay clinic trial initi enrol unexpect
safeti issu efficaci lower expect upsid risk upcom data pivot data could prove efficaci look earlier stage
studi also possibl data competitor could look wors expect unexpect safeti issu could emerg could benefit bmrn
competit posit regulatori risk downsid risk clinic trial ultim success possibl bmrn medicin approv global
regulatori agenc given novelti certain medicin develop regulatori agenc may requir addit long-term data could delay
potenti approv upsid risk hand regulatori process could go faster smoothli expect ip risk downsid risk depend
intellectu properti protect control trade secret technolog innov inabl defend patent could result increas gener
competit addit compani may accus infring ip upsid risk compani could defend ip prevail legal proceed
celg neutral valuat valu celg use discount cash flow analysi util wacc termin growth rate valu
commerci product select upcom pipelin asset use sum-of-the-part method valu celg whole upsid risk upsid risk rate
valuat celg includ celg obtain higher acquisit offer bmi share price increas current close price given share-bas
compon propos acquisit potenti faster regulatori approv expect investor three ozanimod lisocel
would increas present valu cvr downsid risk downsid risk valuat includ bmi share price declin current close price
neutral valuat rate neutral continu struggl meaning grow rubraca sale approv indic
outlook like improv near term competitor drug gain traction front-lin ovarian cancer treatment run broad
develop program aim expand rubraca use type cancer trial complet risk downsid risk
regulatori commerci setback potenti emerg new competitor dilut financ beyond assum upsid risk pipelin success
beyond alreadi account model acquir
buy valuat valu inc per share use dcf base valuat method valuat includ commerci product
cabometyx cometriq well probability-adjust cash flow deriv compani pipelin royalti out-licens program use
discount rate termin growth rate appli termin year post-assum gener entri cabozantinib risk risk valuat
inc includ regulatori commerci setback potenti emerg new competitor lower product sale expect
buy valuat price target per share base sum-of-the-part peak revenu analysi appli multipl
product global peak sale assum discount rate sum-of-the-part basi arriv galafold fabri diseas commerci
at-gaa pomp diseas po program po po rest valuat come
pipelin platform cash risk suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif includ clinic risk possibl could experi regulatori delay slower
expect clinic trial neg data develop program addit unexpect safeti issu could emerg particularli gene therapi
program read-through broader pipelin regulatori risk clinic trial ultim success possibl medicin
approv global regulatori agenc galafold current acceler approv us possibl compani success gener data
convert full approv given novelti gene therapi technolog agenc may requir addit long-term data could delay potenti
approv ip risk ip use galafold treat fabri diseas monotherapi expir us expir europ japan
right patent possibl robust gene therapi aav vector-gen therapi landscap rapidli evolv
page analyst certif import disclosur
guarante access new develop technolog emerg space manufactur risk manufactur complex biolog
viral vector gene therapi complic expens possibl could encount stumbl block along way particularli gene
therapi program compani work translat academ program larger scale manufactur headlin risk aav vector-gen therapi technolog
wide follow public media possibl news technolog unrel could lead downsid share
buy valuat price target per share prev base dcf analysi forecast probability-weight revenu
expens assum discount rate termin growth rate invest risk suscept risk appli
entir biotech industri includ develop regulatori commerci manufactur financ ip risk specif includ commerci risk
possibl may fail introduc new product market current product could produc less revenu expect patient identif may slower
expect product may receiv unfavor payor reimburs clinic risk sever key pipelin product still clinic develop may
delay clinic trial initi enrol unexpect safeti issu efficaci lower expect regulatori risk clinic trial ultim
success possibl gild medicin approv global regulatori agenc agenc may requir addit long-term data could
delay potenti approv ip risk depend intellectu properti protect control trade secret technolog innov inabl
defend patent could result increas gener competit addit compani may accus infring ip current sever legal
proceed relat product competitor risk hiv hcv busi repres signific amount total product sale mix could face
increas competit aggress competit face signific competit therapi develop includ liver diseas inflamm
oncolog multipl compani develop therapi could prove better safeti efficaci move faster market
gmab dc buy valuat valu gmab-dk dkk per share base dcf analysi use probability-adjust free cash flow project
darzalex royalti tisotumab vedotin enapotamab vedotin duobodi asset hexabodi asset royalti partnerships/collabor averag
discount rate risk regulatori commerci setback potenti emerg new competitor lower product sale expect
risk intellectu properti risk manag execut
gwph buy valuat pt gwph base sum-of-the-part sotp net-present-valu npv analysi includ probability-adjust
npv epidiolex dravet lennox-gastaut treatment resist seizur technolog valu compani anticip net cash
posit use discount rate termin valu believ appropri similar stage compani risk includ regulatori
commerci setback potenti emerg new competitor financ becom cash flow posit biotech compani carri risk need rais
money market public and/or privat
buy valuat valu per share use probabl adjust free cash flow project jakafi iclusig olumi itacitinib
topic ruxolitinib use discount rate consist commerci stage biotech compani coverag termin growth rate
risk regulatori commerci setback potenti emerg new competitor lower product sale expect risk intellectu properti
risk manag execut
buy valuat valu use sum-of-the-part valuat discount rate line similar stage biotech compani
risk regulatori and/or commerci setback unproven mechan lead program contribut valuat dilut financ beyond
assum
neutral valuat pt base sum-of-the-part sotp net-present-valu npv analysi includ probability-adjust
npv ingrezza orlissa royalti opicapon technolog valu compani anticip net cash posit use
discount rate zero termin valu believ appropri similar stage compani upsid price target current level
maintain neutral rate base lack near term catalyst could larg impact share price
page analyst certif import disclosur
upsid risk includ ingrezza and/or orilissa sale grow faster expect approv indic potenti acquisit downsid risk includ
regulatori commerci setback potenti emerg new competitor financ
neutral valuat valu use discount cash flow analysi though valuat includ commerci product nerlynx well
probability-adjust cash flow potenti label expans use wacc consist commerci stage compani cover
well termin growth rate upsid risk upsid risk valuat includ higher-than-expect volum uptak emerg new
pipelin agent valuat potenti acquisit premium downsid risk downsid risk valuat includ regulatori
commerci setback potenti emerg new competitor lower product sale expect
buy valuat pt assum trade mean similar stage compani non-gaap ep estim
support risk-adjust npv forward price-to-earnings compar analysi yield pt risk downsid risk includ failur secur approv
eylea/dupixent/libtayo addit indic
buy valuat pt base sum-of-the-part sotp net-present-valu npv analysi includ probability-adjust npv
mdd technolog valu compani anticip net cash posit use discount rate
termin valu believ appropri similar stage compani risk includ regulatori commerci setback potenti emerg new
competitor financ becom cash flow posit biotech compani carri risk need rais money market public and/or privat
buy valuat valu per share use dcf base valuat method increas sale forecast
enfortumab vedotin follow strong data present esmo congress increas confid drug candid move muc
valuat includ commerci product adcetri well probability-adjust cash flow deriv compani pipelin use discount rate
consist commerci stage biotech compani coverag termin growth rate appli termin year post-assum
adcetri biosimilar entri risk risk valuat includ regulatori commerci setback potenti emerg new
competitor /or lower product sale expect risk intellectu properti risk manag execut misstep
neutral valuat base dcf analysi believ fairli valu forecast probability-weight revenu expens
assum discount rate termin growth rate po cf tripl therapi po gene therapi risk suscept
risk appli entir biotech industri includ develop regulatori commerci manufactur financ ip risk specif
includ clinic risk delay clinic trial initi unexpect safeti issu efficaci lower expect regulatori risk clinic trial
ultim success possibl vrtx medicin approv global regulatori agenc given novelti technolog agenc may
requir addit long-term data could delay potenti approv ip risk crispr landscap rapidli evolv guarante
access new develop technolog emerg space competitor risk technolog wide follow
public media possibl news technolog unrel /crsp could lead downsid share
zeal-dk buy valuat valu zeal-dk dkk use sum-of-the-part valuat discount rate line similar stage biotech
compani risk regulatori and/or commerci setback unfavor competit dynam exist emerg new competitor dilut financ
beyond assum
page analyst certif import disclosur
mm except per share data
factset consensu
incom tax
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
page analyst certif import disclosur
inc yatin suneja complement total yoy yoy metabol franchis qoq yoy total revenu gross oper oper incom non-gaap tax incom loss net incom net gaap qoq yoy incom includ stock includ stock ep exclud stock-comp item compani report guggenheim secur llc estim mm except per share unit
page analyst certif import disclosur
interferon ms product rituxan/gazyva sale right incom interest net incom ep stock tax net incom includ non-cash stock ep includ stock share outstand ep exclud stock-comp items- consensusrevenu compani report guggenheim secur llc estim mm except per share unitsyatin suneja
mm except per share data
royalti revenu
factset consensu
total incom expens net
incom tax
net incom attribut
factset consensu
cog
sg
tax
non-gaap net incom attribut
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
amort acquir intang asset
acquisition-rel charg restructur
total cost expens
interest invest incom net
compani report guggenheim secur llc estim
page analyst certif import disclosur
sg product sale
 revenu
cog product sale
soe sg
compani report guggenheim secur llc estim
page analyst certif import disclosur
cash equival
properti plant equip net
short-term borrow current portion long-term debt
accru expens current liabil
long-term debt net discount
compani report guggenheim secur llc estim
page analyst certif import disclosur
chang
flow oper
account payabl oper liabil
flow invest activ
increase/decreas secur intang fin asset
flow financ activ
payment treasuri share
net payment/proce show term borrow
proce long term debt issu
princip repay current portion long-term debt
effect currenc rate chang cash cash equival
compani report guggenheim secur llc estim
page analyst certif import disclosur
mm except per share data
factset consensu
total incom expens net
incom tax ebit
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
mm except per share data
royalti contract revenu
factset consensu
total incom expens net
incom tax
net loss attribut non-controlling interest
net incom attribut
cog
sg
pre-tax adjustmentstax
non-gaap net incom attribut
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
total cost expens
total incom expens
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
